← Leaderboards
Alexander M Cole
University Of California Los Angeles
$10,641,954
Attributed
$10,641,954
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2005–21$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$10,641,954 · 12
By mechanism
R01$4,846,596 · 3
U19$2,369,227 · 2
R21$1,660,075 · 4
R33$1,374,343 · 1
R56$382,609 · 1
F32$9,104 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Ben J Glasgow$7,642,088
- Robert Irving Lehrer$5,468,942
- Michael F Carey$13,509,079
- William Hsu$2,700,990
- Alan J Waring$588,635
Others in their field
Top investigators on “Surface”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Lawrence Corey · Fred Hutchinson Cancer Center$207,726,216
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$118,664,913
Research focus
SurfaceMucous MembranePeptidesBaseIn VivoIn VitroPreventCellsInhibitor/AntagonistTransmission ProcessInfectionTissuesEpithelial CellsDefensinsRetrocyclinHiv-1Liquid SubstanceVaginaAffectPilot ProjectsAttentionResistanceMediatingProphylactic
Grant awards (38)
Bacterial vaginosis induces matrix metalloproteinases that enhance HIV infection in women$222,483
R21 · FY2021 · AI · contact PI
Bacterial vaginosis induces matrix metalloproteinases that enhance HIV infection in women$185,614
R21 · FY2020 · AI · contact PI
Augmenting innate immunity to combat nasal carriage of Staphylococcus aureus$219,000
R21 · FY2017 · AI · contact PI
Development of nonhuman primate model of S. aureus nasal carriage$196,893
R21 · FY2016 · AI · contact PI
Augmenting innate immunity to combat nasal carriage of Staphylococcus aureus$182,500
R21 · FY2016 · AI · contact PI
Development of nonhuman primate model of S. aureus nasal carriage$261,352
R21 · FY2015 · AI · contact PI
Aminoglycoside microbicides restore natural expression of anti-HIV-1 retrocyclins$435,988
R33 · FY2013 · AI · contact PI
Aminoglycoside microbicides restore natural expression of anti-HIV-1 retrocyclins$470,985
R33 · FY2012 · AI · contact PI
Development of RC-101 as an Intravaginal Anti-HIV-1 Topical Microbicide$405,034
U19 · FY2012 · AI · contact PI
Aminoglycoside microbicides restore natural expression of anti-HIV-1 retrocyclins$467,370
R33 · FY2011 · AI · contact PI
Retrocyclins: circular defensins active against HIV-1$382,609
R56 · FY2011 · AI · contact PI
Development of RC-101 as an Intravaginal Anti-HIV-1 Topical Microbicide$372,527
U19 · FY2011 · AI · contact PI
Development of RC-101 as an Intravaginal Anti-HIV-1 Topical Microbicide$430,020
U19 · FY2010 · AI · contact PI
Retrocyclins: circular defensins active against HIV-1$339,225
R01 · FY2010 · AI · contact PI
Nasal carriage of S. aureus: host-pathogen interactions$303,419
R01 · FY2010 · AI · contact PI
Aminoglycoside microbicides restore natural expression of anti-HIV-1 retrocyclins$198,713
R21 · FY2010 · AI · contact PI
Development of RC-101 as an Intravaginal Anti-HIV-1 Topical Microbicide$402,359
U19 · FY2009 · AI · contact PI
Retrocyclins: circular defensins active against HIV-1$342,651
R01 · FY2009 · AI · contact PI
Nasal carriage of S. aureus: host-pathogen interactions$306,483
R01 · FY2009 · AI · contact PI
Aminoglycoside microbicides restore natural expression of anti-HIV-1 retrocyclins$193,520
R21 · FY2009 · AI · contact PI
Retrocyclins: circular defensins active against HIV-1$342,651
R01 · FY2008 · AI · contact PI
Nasal carriage of S. aureus: host-pathogen interactions$306,483
R01 · FY2008 · AI · contact PI
DEVELOPMENT OF RETROCYCLIN MICROBICIDES$187,366
U19 · FY2008 · AI · contact PI
Retrocyclins: circular defensins active against HIV-1$349,632
R01 · FY2007 · AI · contact PI
Nasal carriage of S. aureus: host-pathogen interactions$312,419
R01 · FY2007 · AI · contact PI
DEVELOPMENT OF RETROCYCLIN MICROBICIDES$193,104
U19 · FY2007 · AI · contact PI
Retrocyclins: circular defensins active against HIV-1$372,593
R01 · FY2006 · AI · contact PI
Nasal carriage of S. aureus: host-pathogen interactions$321,750
R01 · FY2006 · AI · contact PI
DEVELOPMENT OF RETROCYCLIN MICROBICIDES$186,824
U19 · FY2006 · AI · contact PI
Retrocyclins: Circular Defensins Active Against HIV-1$300,959
R01 · FY2005 · AI
DEVELOPMENT OF RETROCYCLIN MICROBICIDES$191,993
U19 · FY2005 · AI
Retrocyclins: Circular Defensins Active Against HIV-1$301,253
R01 · FY2004 · AI
Retrocyclins: Circular Defensins Active Against HIV-1$271,559
R01 · FY2003 · AI
Proteomics of Staphylococcus aureus nasal carriage$152,500
R01 · FY2003 · HL
Retrocyclins: Circular Defensins Active Against HIV-1$27,081
R01 · FY2003 · AI
Retrocyclins: Circular Defensins Active Against HIV-1$343,313
R01 · FY2002 · AI
Proteomics of Staphylococcus aureus nasal carriage$152,625
R01 · FY2002 · HL
ANTIMICROBIAL AGENTS IN CYSTIC FIBROSIS AIRWAYS$9,104
F32 · FY2000 · HL